Payment overview · 2025
General Payments
$2,939.83
153 reported records · 24 companies
Healthcare provider profile · identity verified
Job Mongare, M.D.
Allopathic & Osteopathic Physicians|Psychiatry & Neurology|Neurology · ATHENS, TX · NPI 1962463869
Verified facts
What the public records show
CMS Open Payments records show Job Mongare, M.D. received $2,939.83 in general payments during 2025 across 153 reported records.
EMD Serono, Inc. accounted for 12.8% of that reported general-payment amount.
The Open Payments records used for this analysis explicitly named 27 associated products.
A separate comparison found the same explicitly named product in public Medicare Part D data: Botox, Ingrezza, Nuplazid, Nurtec Odt, Qulipta, Ubrelvy, Zavzpret.
ABBVIE INC. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported BOTOX as an associated drug or biological on 140321 records involving 30103 distinct recipient NPIs. Public Medicare Part D data also shows 31 claims for Botox by this doctor in 2024.
ABBVIE INC. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported QULIPTA as an associated drug or biological on 298617 records involving 58957 distinct recipient NPIs. Public Medicare Part D data also shows 71 claims for Qulipta by this doctor in 2024.
ABBVIE INC. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported UBRELVY as an associated drug or biological on 299803 records involving 61203 distinct recipient NPIs. Public Medicare Part D data also shows 27 claims for Ubrelvy by this doctor in 2024.
ACADIA Pharmaceuticals Inc reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported NUPLAZID as an associated drug or biological on 20845 records involving 6448 distinct recipient NPIs. Public Medicare Part D data also shows 96 claims for Nuplazid by this doctor in 2024.
Neurocrine BioSciences, Inc. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported INGREZZA as an associated drug or biological on 126456 records involving 27390 distinct recipient NPIs. Public Medicare Part D data also shows 41 claims for Ingrezza by this doctor in 2024.
PFIZER INC. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported NURTEC ODT as an associated drug or biological on 217574 records involving 54025 distinct recipient NPIs. Public Medicare Part D data also shows 53 claims for Nurtec Odt by this doctor in 2024.
PFIZER INC. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported ZAVZPRET as an associated drug or biological on 140787 records involving 33518 distinct recipient NPIs. Public Medicare Part D data also shows 15 claims for Zavzpret by this doctor in 2024.
SK Life Science, Inc. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported XCOPRI as an associated drug or biological on 1992 records involving 782 distinct recipient NPIs. Public Medicare Part D data also shows 12 claims for Xcopri by this doctor in 2024.
These records do not establish that a payment influenced prescribing or medical care.
Separate record types
Research & Ownership
Research Payments (direct recipient): not present in the loaded data
Associated Research Funding (for example, named PI): not present in the loaded data
Ownership / Investment: not present in the loaded data
These categories are never added into the General Payments headline. Associated research funding must not be described as money the doctor personally received unless the source record supports that conclusion.
Who paid this doctor?
Companies in 2025 General Payments
| Reported company | Canonical company | Amount | Share | Records | Year |
|---|---|---|---|---|---|
| EMD Serono, Inc. | Unresolved — no canonical attribution shown | $375.90 | 12.8% | 18 | 2025 |
| Novartis Pharmaceuticals Corporation | Unresolved — no canonical attribution shown | $281.18 | 9.6% | 18 | 2025 |
| ABBVIE INC. | Unresolved — no canonical attribution shown | $274.92 | 9.3% | 19 | 2025 |
| PFIZER INC. | Unresolved — no canonical attribution shown | $237.28 | 8.1% | 15 | 2025 |
| Teva Pharmaceuticals USA, Inc. | Unresolved — no canonical attribution shown | $213.18 | 7.2% | 11 | 2025 |
| Lundbeck LLC | Unresolved — no canonical attribution shown | $195.98 | 6.7% | 10 | 2025 |
| ACADIA Pharmaceuticals Inc | Unresolved — no canonical attribution shown | $175.59 | 6.0% | 9 | 2025 |
| MDD US Operations, LLC | Unresolved — no canonical attribution shown | $143.90 | 4.9% | 8 | 2025 |
| Lilly USA, LLC | Unresolved — no canonical attribution shown | $140.32 | 4.8% | 6 | 2025 |
| Biogen, Inc. | Unresolved — no canonical attribution shown | $115.58 | 3.9% | 6 | 2025 |
| Abbott Laboratories | Unresolved — no canonical attribution shown | $102.35 | 3.5% | 3 | 2025 |
| Celgene Corporation | Unresolved — no canonical attribution shown | $88.92 | 3.0% | 4 | 2025 |
| Eisai Inc. | Unresolved — no canonical attribution shown | $82.34 | 2.8% | 4 | 2025 |
| SpringWorks Therapeutics, Inc. | Unresolved — no canonical attribution shown | $80.56 | 2.7% | 3 | 2025 |
| SK Life Science, Inc. |
SK Life Science, Inc. exact · evidence 2025-04-03 |
$71.11 | 2.4% | 3 | 2025 |
| Otsuka America Pharmaceutical, Inc. | Unresolved — no canonical attribution shown | $59.66 | 2.0% | 2 | 2025 |
| Genentech USA, Inc. | Unresolved — no canonical attribution shown | $58.28 | 2.0% | 2 | 2025 |
| Amgen Inc. | Unresolved — no canonical attribution shown | $57.02 | 1.9% | 3 | 2025 |
| Neurocrine BioSciences, Inc. | Unresolved — no canonical attribution shown | $47.96 | 1.6% | 2 | 2025 |
| Averitas Pharma Inc. | Unresolved — no canonical attribution shown | $41.87 | 1.4% | 2 | 2025 |
| Axsome Therapeutics, Inc. | Unresolved — no canonical attribution shown | $35.43 | 1.2% | 2 | 2025 |
| Boston Scientific Corporation | Unresolved — no canonical attribution shown | $26.89 | 0.9% | 1 | 2025 |
| LivaNova USA, Inc. | Unresolved — no canonical attribution shown | $19.40 | 0.7% | 1 | 2025 |
| GE HEALTHCARE | Unresolved — no canonical attribution shown | $14.21 | 0.5% | 1 | 2025 |
What were the payments for?
Payment categories
| Category | Amount | Records |
|---|---|---|
| Food and Beverage | $2,903.50 | 152 |
| Education | $36.33 | 1 |
A meal, consulting fee, royalty, and travel payment describe different kinds of reported relationships and should not be interpreted as equivalent.
Analysis 1 · Payment-linked products
Products named in Open Payments records
| Reported product | Type | Reported company | Related amount* | Records | Year |
|---|---|---|---|---|---|
| KESIMPTA Normalized: kesimpta |
Drug | Novartis Pharmaceuticals Corporation | $281.18 | 18 | 2025 |
Source payment records
|
|||||
| NURTEC ODT Normalized: nurtec odt |
Drug | PFIZER INC. | $237.28 | 15 | 2025 |
Source payment records
|
|||||
| ZAVZPRET Normalized: zavzpret |
Drug | PFIZER INC. | $237.28 | 15 | 2025 |
Source payment records
|
|||||
| QULIPTA Normalized: qulipta |
Drug | ABBVIE INC. | $226.32 | 16 | 2025 |
Source payment records
|
|||||
| VYEPTI Normalized: vyepti |
Biological | Lundbeck LLC | $195.98 | 10 | 2025 |
Source payment records
|
|||||
| UBRELVY Normalized: ubrelvy |
Drug | ABBVIE INC. | $177.69 | 14 | 2025 |
Source payment records
|
|||||
| NUPLAZID Normalized: nuplazid |
Drug | ACADIA Pharmaceuticals Inc | $175.59 | 9 | 2025 |
Source payment records
|
|||||
| KISUNLA Normalized: kisunla |
Drug | Lilly USA, LLC | $140.32 | 6 | 2025 |
Source payment records
|
|||||
| TYSABRI Normalized: tysabri |
Biological | Biogen, Inc. | $115.58 | 6 | 2025 |
Source payment records
|
|||||
| AUSTEDO XR Normalized: austedo xr |
Drug | Teva Pharmaceuticals USA, Inc. | $108.66 | 6 | 2025 |
Source payment records
|
|||||
| AJOVY Normalized: ajovy |
Biological | Teva Pharmaceuticals USA, Inc. | $104.52 | 5 | 2025 |
Source payment records
|
|||||
| INFINITY Normalized: infinity |
Device | Abbott Laboratories | $102.35 | 3 | 2025 |
Source payment records
|
|||||
| VUMERITY Normalized: vumerity |
Drug | Biogen, Inc. | $97.58 | 5 | 2025 |
Source payment records
|
|||||
| ZEPOSIA Normalized: zeposia |
Drug | Celgene Corporation | $88.92 | 4 | 2025 |
Source payment records
|
|||||
| Leqembi Normalized: leqembi |
Drug | Eisai Inc. | $82.34 | 4 | 2025 |
Source payment records
|
|||||
| GOMEKLI Normalized: gomekli |
Drug | SpringWorks Therapeutics, Inc. | $80.56 | 3 | 2025 |
Source payment records
|
|||||
| REXULTI Normalized: rexulti |
Drug | Otsuka America Pharmaceutical, Inc. | $59.66 | 2 | 2025 |
Source payment records
|
|||||
| Ocrevus Zunovo Normalized: ocrevus zunovo |
Biological | Genentech USA, Inc. | $58.28 | 2 | 2025 |
Source payment records
|
|||||
| UPLIZNA Normalized: uplizna |
Biological | Amgen Inc. | $57.02 | 3 | 2025 |
Source payment records
|
|||||
| INGREZZA Normalized: ingrezza |
Drug | Neurocrine BioSciences, Inc. | $47.96 | 2 | 2025 |
Source payment records
|
|||||
| QUTENZA Normalized: qutenza |
Drug | Averitas Pharma Inc. | $41.87 | 2 | 2025 |
Source payment records
|
|||||
| Gocovri Normalized: gocovri |
Drug | MDD US Operations, LLC | $36.34 | 2 | 2025 |
Source payment records
|
|||||
| Symbravo Normalized: symbravo |
Drug | Axsome Therapeutics, Inc. | $35.43 | 2 | 2025 |
Source payment records
|
|||||
| VYALEV Normalized: vyalev |
Drug | ABBVIE INC. | $31.86 | 2 | 2025 |
Source payment records
|
|||||
| BOTOX Normalized: botox |
Biological | ABBVIE INC. | $31.70 | 1 | 2025 |
Source payment records
|
|||||
| General - DBS Normalized: general dbs |
Device | Boston Scientific Corporation | $26.89 | 1 | 2025 |
Source payment records
|
|||||
| VNS THERAPY SENTIVA MODEL 1000 GENERATOR Normalized: vns therapy sentiva model 1000 generator |
Device | LivaNova USA, Inc. | $19.40 | 1 | 2025 |
Source payment records
|
|||||
* Product-associated amounts are non-additive because one payment record may name more than one product.
These products were named on specific Open Payments records. A named product does not show that the payment influenced treatment or prescribing.
Public prescribing for products named in payments
| Open Payments product | Payment year | Part D brand | Part D year | Claims | Match method | Source |
|---|---|---|---|---|---|---|
| BOTOX botox |
2025 | Botox | 2024 | 31 | exact normalized | Medicare Part D |
| INGREZZA ingrezza |
2025 | Ingrezza | 2024 | 41 Beneficiary count suppressed |
exact normalized | Medicare Part D |
| NUPLAZID nuplazid |
2025 | Nuplazid | 2024 | 96 Beneficiary count suppressed |
exact normalized | Medicare Part D |
| NURTEC ODT nurtec odt |
2025 | Nurtec Odt | 2024 | 53 | exact normalized | Medicare Part D |
| QULIPTA qulipta |
2025 | Qulipta | 2024 | 71 | exact normalized | Medicare Part D |
| UBRELVY ubrelvy |
2025 | Ubrelvy | 2024 | 27 Beneficiary count suppressed |
exact normalized | Medicare Part D |
| ZAVZPRET zavzpret |
2025 | Zavzpret | 2024 | 15 Beneficiary count suppressed |
exact normalized | Medicare Part D |
The presence of the same drug in both datasets does not show that a payment caused or influenced a prescription.
Analysis 2 · Same-company prescribing overlap
Drugs reported in other payments from the same company that also appear in Medicare Part D
This analysis is independent from products named on this doctor’s individual payment records. A row appears only when the exact Open Payments reporting entity paid this doctor, that same reporting entity reported the drug or biological on at least 10 loaded General Payment records involving at least 2 distinct recipient NPIs, and this doctor has the same non-generic brand in public Part D data. This does not mean the company owns or manufactures the drug.
| Paying company | Payment year | Drug reported by same entity | Open Payments evidence | Part D | Claims | Beneficiaries |
|---|---|---|---|---|---|---|
| ABBVIE INC. Exact reporting entity; no affiliate inference |
2025 | BOTOX open payments reported associated product |
CMS Open Payments — General Payments 140321 supporting records · 30103 recipient NPIs · example record 1201352642 |
Botox · 2024 Exact normalized brand match · 1 Part D row |
31 | 11 |
| ABBVIE INC. Exact reporting entity; no affiliate inference |
2025 | QULIPTA open payments reported associated product |
CMS Open Payments — General Payments 298617 supporting records · 58957 recipient NPIs · example record 1201352530 |
Qulipta · 2024 Exact normalized brand match · 1 Part D row |
71 | 17 |
| ABBVIE INC. Exact reporting entity; no affiliate inference |
2025 | UBRELVY open payments reported associated product |
CMS Open Payments — General Payments 299803 supporting records · 61203 recipient NPIs · example record 1201352530 |
Ubrelvy · 2024 Exact normalized brand match · 1 Part D row |
27 | suppressed by CMS |
| ACADIA Pharmaceuticals Inc Exact reporting entity; no affiliate inference |
2025 | NUPLAZID open payments reported associated product |
CMS Open Payments — General Payments 20845 supporting records · 6448 recipient NPIs · example record 1247763852 |
Nuplazid · 2024 Exact normalized brand match · 1 Part D row |
96 | suppressed by CMS |
| Neurocrine BioSciences, Inc. Exact reporting entity; no affiliate inference |
2025 | INGREZZA open payments reported associated product |
CMS Open Payments — General Payments 126456 supporting records · 27390 recipient NPIs · example record 1242766729 |
Ingrezza · 2024 Exact normalized brand match · 1 Part D row |
41 | suppressed by CMS |
| PFIZER INC. Exact reporting entity; no affiliate inference |
2025 | NURTEC ODT open payments reported associated product |
CMS Open Payments — General Payments 217574 supporting records · 54025 recipient NPIs · example record 1228794063 |
Nurtec Odt · 2024 Exact normalized brand match · 1 Part D row |
53 | 16 |
| PFIZER INC. Exact reporting entity; no affiliate inference |
2025 | ZAVZPRET open payments reported associated product |
CMS Open Payments — General Payments 140787 supporting records · 33518 recipient NPIs · example record 1228794071 |
Zavzpret · 2024 Exact normalized brand match · 1 Part D row |
15 | suppressed by CMS |
| SK Life Science, Inc. Exact reporting entity; no affiliate inference |
2025 | XCOPRI open payments reported associated product |
CMS Open Payments — General Payments 1992 supporting records · 782 recipient NPIs · example record 1252276115 |
Xcopri · 2024 Exact normalized brand match · 1 Part D row |
12 | suppressed by CMS |
These facts do not show that a payment was for the drug, that the company owns or manufactures the drug, or that a payment caused or influenced prescribing.
Public Medicare Part D data
Provider-and-drug rows loaded for 2024
| Brand | Generic | Claims | Beneficiaries |
|---|---|---|---|
| Memantine Hcl | Memantine Hcl | 405 | 132 |
| Carbidopa-Levodopa | Carbidopa/Levodopa | 292 | 83 |
| Rytary | Carbidopa/Levodopa | 248 | 61 |
| Hydrocodone-Acetaminophen | Hydrocodone/Acetaminophen | 210 | 25 |
| Donepezil Hcl | Donepezil Hcl | 202 | 67 |
| Gabapentin | Gabapentin | 174 | 43 |
| Lamotrigine | Lamotrigine | 151 | 39 |
| Levetiracetam | Levetiracetam | 147 | 37 |
| Lorazepam | Lorazepam | 141 | 38 |
| Alprazolam | Alprazolam | 96 | 11 |
| Nuplazid | Pimavanserin Tartrate | 96 | suppressed |
| Baclofen | Baclofen | 90 | 20 |
| Diazepam | Diazepam | 83 | 35 |
| Topiramate | Topiramate | 83 | 18 |
| Citalopram Hbr | Citalopram Hydrobromide | 75 | 15 |
| Pregabalin | Pregabalin | 71 | 22 |
| Qulipta | Atogepant | 71 | 17 |
| Temazepam | Temazepam | 69 | 14 |
| Primidone | Primidone | 67 | 14 |
| Pramipexole Dihydrochloride | Pramipexole Di-Hcl | 64 | 16 |
| Clonazepam | Clonazepam | 63 | suppressed |
| Phenytoin Sodium Extended | Phenytoin Sodium Extended | 62 | 14 |
| Meclizine Hcl | Meclizine Hcl | 61 | 24 |
| Rivastigmine | Rivastigmine Tartrate | 61 | 16 |
| Cyclobenzaprine Hcl | Cyclobenzaprine Hcl | 57 | 22 |
| Lacosamide | Lacosamide | 54 | suppressed |
| Namzaric | Memantine Hcl/Donepezil Hcl | 54 | 13 |
| Nurtec Odt | Rimegepant Sulfate | 53 | 16 |
| Duloxetine Hcl | Duloxetine Hcl | 52 | 12 |
| Propranolol Hcl | Propranolol Hcl | 52 | 22 |
| Quetiapine Fumarate | Quetiapine Fumarate | 51 | 18 |
| Bupropion Hcl Sr | Bupropion Hcl | 50 | suppressed |
| Prednisone | Prednisone | 50 | 15 |
| Ropinirole Hcl | Ropinirole Hcl | 46 | 16 |
| Midodrine Hcl | Midodrine Hcl | 42 | 11 |
| Ingrezza | Valbenazine Tosylate | 41 | suppressed |
| Amitriptyline Hcl | Amitriptyline Hcl | 40 | 12 |
| Divalproex Sodium Er | Divalproex Sodium | 39 | suppressed |
| Sumatriptan Succinate | Sumatriptan Succinate | 39 | 17 |
| Aimovig Autoinjector | Erenumab-Aooe | 36 | suppressed |
| Droxidopa | Droxidopa | 34 | suppressed |
| Kesimpta Pen | Ofatumumab | 34 | suppressed |
| Zolpidem Tartrate | Zolpidem Tartrate | 34 | suppressed |
| Carbamazepine | Carbamazepine | 33 | suppressed |
| Tizanidine Hcl | Tizanidine Hcl | 33 | 13 |
| Carbamazepine Er | Carbamazepine | 32 | suppressed |
| Phenobarbital | Phenobarbital | 32 | suppressed |
| Botox | Onabotulinumtoxina | 31 | 11 |
| Ondansetron Hcl | Ondansetron Hcl | 31 | suppressed |
| Trazodone Hcl | Trazodone Hcl | 31 | suppressed |
| Cyanocobalamin Injection | Cyanocobalamin (Vitamin B-12) | 30 | suppressed |
| Celecoxib | Celecoxib | 29 | suppressed |
| Emgality Pen | Galcanezumab-Gnlm | 29 | suppressed |
| Buprenorphine Hcl | Buprenorphine Hcl | 28 | suppressed |
| Memantine Hcl Er | Memantine Hcl | 28 | suppressed |
| Oxcarbazepine | Oxcarbazepine | 28 | suppressed |
| Carisoprodol | Carisoprodol | 27 | suppressed |
| Ubrelvy | Ubrogepant | 27 | suppressed |
| Armodafinil | Armodafinil | 24 | suppressed |
| Buspirone Hcl | Buspirone Hcl | 24 | suppressed |
| Paroxetine Hcl | Paroxetine Hcl | 24 | suppressed |
| Tramadol Hcl | Tramadol Hcl | 24 | 11 |
| Amantadine | Amantadine Hcl | 23 | suppressed |
| Dalfampridine Er | Dalfampridine | 23 | suppressed |
| Modafinil | Modafinil | 23 | suppressed |
| Oxycodone Hcl | Oxycodone Hcl | 23 | suppressed |
| Escitalopram Oxalate | Escitalopram Oxalate | 22 | suppressed |
| Rizatriptan | Rizatriptan Benzoate | 22 | suppressed |
| Ajovy Autoinjector | Fremanezumab-Vfrm | 21 | suppressed |
| Pyridostigmine Bromide Er | Pyridostigmine Bromide | 21 | suppressed |
| Oxycodone-Acetaminophen | Oxycodone Hcl/Acetaminophen | 20 | suppressed |
| Carbidopa-Levodopa Er | Carbidopa/Levodopa | 19 | suppressed |
| Lisinopril | Lisinopril | 19 | suppressed |
| Megestrol Acetate | Megestrol Acetate | 19 | suppressed |
| Neupro | Rotigotine | 19 | suppressed |
| Pyridostigmine Bromide | Pyridostigmine Bromide | 19 | suppressed |
| Risperidone | Risperidone | 19 | suppressed |
| Methylphenidate Hcl | Methylphenidate Hcl | 18 | suppressed |
| Naproxen | Naproxen | 18 | suppressed |
| Clopidogrel | Clopidogrel Bisulfate | 17 | suppressed |
| Methocarbamol | Methocarbamol | 17 | suppressed |
| Scopolamine | Scopolamine | 17 | suppressed |
| Dextroamphetamine-Amphet Er | Dextroamphetamine/Amphetamine | 16 | suppressed |
| Dilantin | Phenytoin Sodium Extended | 16 | suppressed |
| Buprenorphine-Naloxone | Buprenorphine Hcl/Naloxone Hcl | 15 | suppressed |
| Fingolimod | Fingolimod Hcl | 15 | suppressed |
| Zavzpret | Zavegepant Hcl | 15 | suppressed |
| Butalb-Acetaminoph-Caff-Codein | Butalbit/Acetamin/Caff/Codeine | 14 | suppressed |
| Divalproex Sodium | Divalproex Sodium | 14 | suppressed |
| Methadone Hcl | Methadone Hcl | 14 | suppressed |
| Omeprazole | Omeprazole | 14 | suppressed |
| Oxybutynin Chloride Er | Oxybutynin Chloride | 14 | suppressed |
| Aripiprazole | Aripiprazole | 13 | suppressed |
| Gammaked | Immune Globul G/Gly/Iga Avg 46 | 13 | suppressed |
| Meloxicam | Meloxicam | 13 | suppressed |
| Methylprednisolone | Methylprednisolone | 13 | suppressed |
| Myrbetriq | Mirabegron | 13 | suppressed |
| Oxtellar Xr | Oxcarbazepine | 13 | suppressed |
| Pantoprazole Sodium | Pantoprazole Sodium | 13 | suppressed |
| Zubsolv | Buprenorphine Hcl/Naloxone Hcl | 13 | suppressed |
| Ajovy Syringe | Fremanezumab-Vfrm | 12 | suppressed |
| Butalbital-Acetaminophen-Caffe | Butalb/Acetaminophen/Caffeine | 12 | suppressed |
| Diclofenac Sodium | Diclofenac Sodium | 12 | suppressed |
| Emgality Syringe | Galcanezumab-Gnlm | 12 | suppressed |
| Fluticasone Propionate | Fluticasone Propionate | 12 | suppressed |
| Lamotrigine Er | Lamotrigine | 12 | suppressed |
| Morphine Sulfate Er | Morphine Sulfate | 12 | suppressed |
| Ondansetron Odt | Ondansetron | 12 | suppressed |
| Rebif | Interferon Beta-1a/Albumin | 12 | suppressed |
| Rebif Rebidose | Interferon Beta-1a/Albumin | 12 | suppressed |
| Trokendi Xr | Topiramate | 12 | suppressed |
| Xcopri | Cenobamate | 12 | suppressed |
| Zonisamide | Zonisamide | 12 | suppressed |
| Avonex (4 Pack) | Interferon Beta-1a | 11 | suppressed |
| Furosemide | Furosemide | 11 | suppressed |
| Losartan Potassium | Losartan Potassium | 11 | suppressed |
| Ongentys | Opicapone | 11 | suppressed |
| Risedronate Sodium | Risedronate Sodium | 11 | suppressed |
| Venlafaxine Hcl Er | Venlafaxine Hcl | 11 | suppressed |
Timeline
Payment and prescribing data by year
Open Payments and Medicare Part D may refer to different years. They are shown separately rather than aligned as if they describe the same period.
| Year | General Payments | Main payer | Explicit products | Company overlaps | Part D coverage |
|---|---|---|---|---|---|
| 2025 | $2,939.83 · 153 records | EMD Serono, Inc. | AJOVY, AUSTEDO XR, BOTOX, GOMEKLI, General - DBS, Gocovri, INFINITY, INGREZZA, KESIMPTA, KISUNLA, Leqembi, NUPLAZID, NURTEC ODT, Ocrevus Zunovo, QULIPTA, QUTENZA, REXULTI, Symbravo, TYSABRI, UBRELVY, UPLIZNA, VNS THERAPY SENTIVA MODEL 1000 GENERATOR, VUMERITY, VYALEV, VYEPTI, ZAVZPRET, ZEPOSIA | 8 | — |
| 2024 | — | — | — | — | Complete |
Questions to ask
Questions you could discuss with your doctor
- What role, if any, does Botox play in your treatment recommendations for me?
- How do you evaluate evidence when you have a financial relationship with ABBVIE INC.?
- Are there reasonable alternatives I should understand when we discuss treatment options?
- How should I interpret the industry-payment records shown here in the context of my care?
These are general questions generated from reviewed templates. They are not personalized medical advice.
Sources and limitations
How to read this page
- Payment and Medicare prescribing data can cover different years; every comparison shows both years explicitly.
- Part D does not represent a doctor’s entire practice; it excludes many patients and is subject to CMS public-release thresholds.
- Company–drug relationships must have an auditable source, a precise relationship type, and a valid evidence period. Unresolved mappings are not published.
- Generic drug claims are not attributed to a specific manufacturer without manufacturer-level evidence.
- When a source extract is incomplete, missing rows are never treated as proof of no payments or no prescriptions.
Loaded source releases
| Dataset | Year | Publication | Source |
|---|---|---|---|
| CMS Open Payments — General Payments | 2025 | 2026-06-30 | Original source |
| Medicare Part D Prescribers by Provider and Drug | 2024 | 2026-05-06 | Original source |
| NPPES Data Dissemination V2 | current / reference data | 2026-08-10 | Original source |
Full methodology · Questions & answers · Report a possible error